DK1261601T3 - Substituerede indoler til modulering af NFKB-aktivitet - Google Patents

Substituerede indoler til modulering af NFKB-aktivitet

Info

Publication number
DK1261601T3
DK1261601T3 DK00974405T DK00974405T DK1261601T3 DK 1261601 T3 DK1261601 T3 DK 1261601T3 DK 00974405 T DK00974405 T DK 00974405T DK 00974405 T DK00974405 T DK 00974405T DK 1261601 T3 DK1261601 T3 DK 1261601T3
Authority
DK
Denmark
Prior art keywords
substituted indoles
nfkb activity
modulating nfkb
modulating
activity
Prior art date
Application number
DK00974405T
Other languages
Danish (da)
English (en)
Inventor
Olaf Ritzeler
Hans Ulrich Stilz
Gerhard Jaehne
Joerg Habermann
Bernhard Neises
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1261601T3 publication Critical patent/DK1261601T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
DK00974405T 1999-10-26 2000-10-17 Substituerede indoler til modulering af NFKB-aktivitet DK1261601T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951360A DE19951360A1 (de) 1999-10-26 1999-10-26 Substituierte Indole
PCT/EP2000/010210 WO2001030774A1 (de) 1999-10-26 2000-10-17 Substituierte indole zur modulierung von nfkb-aktivität

Publications (1)

Publication Number Publication Date
DK1261601T3 true DK1261601T3 (da) 2009-11-16

Family

ID=7926798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00974405T DK1261601T3 (da) 1999-10-26 2000-10-17 Substituerede indoler til modulering af NFKB-aktivitet

Country Status (32)

Country Link
US (3) US20030119820A1 (xx)
EP (1) EP1261601B1 (xx)
JP (1) JP3843012B2 (xx)
KR (1) KR100795709B1 (xx)
CN (1) CN1172929C (xx)
AT (1) ATE437867T1 (xx)
AU (1) AU781553B2 (xx)
BR (1) BR0015026B1 (xx)
CA (1) CA2389165C (xx)
CY (1) CY1110521T1 (xx)
CZ (1) CZ304885B6 (xx)
DE (2) DE19951360A1 (xx)
DK (1) DK1261601T3 (xx)
EE (1) EE05036B1 (xx)
ES (1) ES2329871T3 (xx)
HK (1) HK1049671A1 (xx)
HR (1) HRP20020357B1 (xx)
HU (1) HU229215B1 (xx)
IL (2) IL149272A0 (xx)
ME (1) ME00434B (xx)
MX (1) MXPA02003998A (xx)
NO (1) NO323952B1 (xx)
NZ (1) NZ518587A (xx)
PL (1) PL200115B1 (xx)
PT (1) PT1261601E (xx)
RS (1) RS50424B (xx)
RU (1) RU2255087C2 (xx)
SI (1) SI1261601T1 (xx)
SK (1) SK287116B6 (xx)
TR (1) TR200201144T2 (xx)
WO (1) WO2001030774A1 (xx)
ZA (1) ZA200203204B (xx)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
CA2427284A1 (en) * 2000-10-26 2002-05-30 Tularik Inc. Antiinflammation agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1417200B1 (en) * 2001-08-13 2010-06-02 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
MXPA04006614A (es) 2002-01-07 2004-10-04 Eisai Co Ltd Deazapurinas y usos de las mismas.
ME00355B (me) 2002-06-06 2010-06-30 Ptp Group Ltd Kristalisan polietilen tereftalat, koji sadrži silicijum, i postupak za njegovo dobijanje
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1462105A1 (en) * 2003-03-28 2004-09-29 Procorde GmbH Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases
MXPA05010793A (es) * 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
US7951801B2 (en) 2004-04-09 2011-05-31 Millennium Pharmaceuticals, Inc. Beta-carbolines useful for treating inflammatory disease
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
UA99699C2 (ru) 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Производные индолкарбоксамида и фармацевтическая композиция, которая их содержит
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
US7592353B2 (en) 2006-06-06 2009-09-22 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
DK2119703T3 (da) * 2007-01-15 2013-01-14 Santen Pharmaceutical Co Ltd Nyt indolderivat med inhiberende virkning på I-B-kinase.
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2314575B1 (en) * 2008-07-14 2013-06-19 Santen Pharmaceutical Co., Ltd Novel indole derivative having carbamoyl group, ureido group and substituted oxy group
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
WO2010038465A1 (ja) 2008-10-02 2010-04-08 旭化成ファーマ株式会社 ８位置換イソキノリン誘導体及びその用途
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2010047126A1 (ja) * 2008-10-23 2010-04-29 株式会社ヤクルト本社 フェナンスロインドリジジン誘導体及びこれを有効成分とするＮＦκＢ阻害剤
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010096751A1 (en) * 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR20130099044A (ko) 2010-08-12 2013-09-05 사노피 ２，３­디아미노프로피온산 유도체의 에난티오머 형태의 제조 방법
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN114432423A (zh) * 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
KR20200101398A (ko) * 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물
US20210236398A1 (en) * 2020-01-31 2021-08-05 L'oreal Compositions and methods for hair
FR3107832B1 (fr) * 2020-03-05 2022-04-29 Oreal Compositions et procédés pour les cheveux

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188379T1 (de) * 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
JP3213426B2 (ja) * 1993-02-19 2001-10-02 エーザイ株式会社 ６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
GB9605065D0 (en) * 1996-03-11 1996-05-08 Merck Sharp & Dohme Therapeutic agents
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
CA2262847C (en) * 1996-08-01 2007-06-05 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
ATE264318T1 (de) * 1996-11-19 2004-04-15 Amgen Inc Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
RU2212407C2 (ru) * 1997-11-10 2003-09-20 Бристол-Маерс Сквибб Компани Бензотиазольные ингибиторы протеинтирозинкиназ
CA2322162A1 (en) 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
BR0012450B1 (pt) * 1999-06-23 2011-08-23 benzimidazóis substituìdos.
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
RU2006143758A (ru) 2004-05-12 2008-06-27 Авентис Фармасьютикалз Инк. (Us) По существу чистая 2-{[2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбонил]-амино}-3-(фенилпиридин-2-иламино)-пропионовая кислота в качестве ингибитора 1кв киназы

Also Published As

Publication number Publication date
IL149272A (en) 2007-02-11
CN1379772A (zh) 2002-11-13
US20040209868A1 (en) 2004-10-21
TR200201144T2 (tr) 2003-02-21
CZ304885B6 (cs) 2015-01-07
RU2255087C2 (ru) 2005-06-27
EE05036B1 (et) 2008-06-16
HU229215B1 (en) 2013-09-30
HRP20020357A2 (en) 2004-02-29
ZA200203204B (en) 2002-10-23
HRP20020357B1 (en) 2010-10-31
PT1261601E (pt) 2009-10-15
SI1261601T1 (sl) 2009-12-31
HUP0203228A2 (hu) 2003-02-28
AU781553B2 (en) 2005-05-26
ES2329871T3 (es) 2009-12-02
JP2003519101A (ja) 2003-06-17
NO20021808D0 (no) 2002-04-17
IL149272A0 (en) 2002-11-10
BR0015026B1 (pt) 2011-11-29
AU1272801A (en) 2001-05-08
US20030119820A1 (en) 2003-06-26
EE200200217A (et) 2003-06-16
CA2389165C (en) 2010-11-16
CZ20021413A3 (cs) 2002-07-17
NO20021808L (no) 2002-04-17
EP1261601A1 (de) 2002-12-04
SK5432002A3 (en) 2002-11-06
CN1172929C (zh) 2004-10-27
RS50424B (sr) 2009-12-31
HK1049671A1 (en) 2003-05-23
DE19951360A1 (de) 2001-05-03
BR0015026A (pt) 2002-07-16
ATE437867T1 (de) 2009-08-15
KR20030004302A (ko) 2003-01-14
JP3843012B2 (ja) 2006-11-08
PL200115B1 (pl) 2008-12-31
ME00434B (me) 2011-10-10
MXPA02003998A (es) 2002-10-23
SK287116B6 (sk) 2009-12-07
HUP0203228A3 (en) 2004-01-28
US7342029B2 (en) 2008-03-11
KR100795709B1 (ko) 2008-01-21
WO2001030774A1 (de) 2001-05-03
US20050282866A1 (en) 2005-12-22
DE50015700D1 (de) 2009-09-10
NO323952B1 (no) 2007-07-23
YU21702A (sh) 2004-11-25
CA2389165A1 (en) 2001-05-03
EP1261601B1 (de) 2009-07-29
CY1110521T1 (el) 2015-04-29
NZ518587A (en) 2004-06-25
PL354528A1 (en) 2004-01-26

Similar Documents

Publication Publication Date Title
DK1261601T3 (da) Substituerede indoler til modulering af NFKB-aktivitet
DE50010931D1 (de) Substituierte benzimidazole
BR9707233A (pt) Fenantridinas
ATE233274T1 (de) Oxyiminopregnancarbolactone
DE69725171D1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
MY140074A (en) INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkB KINASE
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
AR023777A1 (es) Nuevos compuestos
DE60028010D1 (de) Verminderung des haarwuchses
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
SE9802208D0 (sv) Novel compounds
NO20022920D0 (no) Nye forbindelser
ATE259813T1 (de) Triazolopyrimidinderivate
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
SE9802209D0 (sv) Novel compounds
ECSP003590A (es) Compuestos calcioliticos
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
SE9802207D0 (sv) Novel compounds
DE69804843D1 (de) Heterozyklische verbidungen mit mmp und tnf inhibitorisher wirkung
PT937075E (pt) Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese
SU1732642A1 (ru) 4-хлоранилид n-ацетил-n-аллилантраниловой кислоты, проявляющий противовоспалительную и анальгетическую активность